Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is reporting third quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, IOVA is expected to report 3Q20 loss of $ 0.46 per share.
For the full year, analysts anticipate loss of $ 1.94 per share bottom line.
Stock Performance
On Friday, shares of Iovance Biotherapeutics, Inc. has traded high as $ 36.06 and has cracked $ 34.36 on the downward trend, reaching $ 35.68 with volume of 892.40 thousand shares.
According to the previous trading day, closing price of $ 35.68, representing a 91.87 % increase from the 52 week low of $ 18.70 and a 13.52 % decrease over the 52 week high of $ 41.49.
The company has a market capital of $ 5.23 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by Wells Fargo & Co at Equal-Weight rating, with $ 35.00 target price.
- On 6th October 2020, maintained by Chardan Capital at Buy rating, with $ 50.00 target price.
- On 6th October 2020, maintained by HC Wainwright at Buy rating, with $ 46.00 target price.
- On 6th October 2020, maintained by Barclays at Overweight rating, with $ 36.00 target price.
- On 6th October 2020, downgraded by Wells Fargo & Co to Equal-Weight from Overweight rating, with $ 29.00 target price.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patients immune system to eradicate cancer cells. The companys lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers.
